Comparative Pharmacology
Head-to-head clinical analysis: EDETATE CALCIUM DISODIUM versus PENTETATE CALCIUM TRISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDETATE CALCIUM DISODIUM versus PENTETATE CALCIUM TRISODIUM.
EDETATE CALCIUM DISODIUM vs PENTETATE CALCIUM TRISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelates heavy metals (e.g., lead, cadmium) by forming stable complexes with divalent and trivalent cations, which are then excreted in urine.
Pentetate calcium trisodium is a chelating agent that forms stable complexes with divalent and trivalent heavy metal ions, such as plutonium, americium, and curium. It enhances the urinary elimination of these metals by increasing the rate of dissociation from tissues and promoting renal excretion.
Edetate calcium disodium is administered intravenously or intramuscularly. For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; alternatively 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Duration typically 5 days, repeat after 2 days rest. For other heavy metal toxicity: 50 mg/kg/day IV or IM in divided doses every 8-12 hours for 3-5 days.
1 g (one vial) intravenously over 1 hour once daily for up to 5 days.
None Documented
None Documented
Terminal elimination half-life approximately 1.5-3 hours for the intact chelate; prolonged to 20-40 hours in lead-intoxicated patients due to redistribution of lead from bone.
Terminal elimination half-life is approximately 0.6-0.8 hours in patients with normal renal function.
Primarily renal (90-100% as chelated lead complex within 24-48 hours); minimal biliary/fecal excretion (<5%).
Primarily renal elimination via glomerular filtration; >90% of absorbed dose excreted unchanged in urine within 24 hours.
Category C
Category C
Chelating Agent
Chelating Agent